Neutrophil Extracellular Trap Production in Patients with Colorectal Cancer In Vitro. by Richardson, J J R et al.
Research Article
Neutrophil Extracellular Trap Production in Patients with
Colorectal Cancer In Vitro
J. J. R. Richardson,1,2 C. Hendrickse,2 F. Gao-Smith,1 and D. R. Thickett1
1 Institute of Inflammation and Ageing, College of Medical and Dental Sciences, The University of Birmingham,
Birmingham B15 2TT, UK
2Department of Colorectal Surgery, Heart of England NHS Foundation Trust, Birmingham B9 5SS, UK
Correspondence should be addressed to J. J. R. Richardson; jonathan.richardson@nhs.net
Received 13 March 2017; Revised 18 June 2017; Accepted 27 June 2017; Published 30 July 2017
Academic Editor: Han J. Moshage
Copyright © 2017 J. J. R. Richardson et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. Neutrophil Extracellular Traps (NETs) are extracellular neutrophil derived DNA webs which have been implicated in
cancer progression and in the development of metastases. NETs production in patients with colorectal cancer was investigated
to elucidate their role and prognostic significance. Methods. Systemic neutrophils were isolated from consecutive patients with
colorectal cancer and from age-matched healthy volunteers. Neutrophils were stimulated to produce NETs which were quantified
by a measure of the fluorescence of the extracellular DNA. The impact of cancer location, tumour stage, and patient outcomes
(complications, length of stay, and mortality) on NET production was investigated. Results. Quantification of NET formation was
performed in patients with colorectal cancer (𝑛 = 45) and in well-matched healthy individuals (𝑛 = 20). Significant increases
in NETs production in response to no stimulant (9,735AFU versus 11347AFU, 𝑝 = 0.0209), IL-8 (8,644AFU versus 11,915 AFU,
𝑝 = 0.0032), and LPS (10,576AFU versus 12,473AFU, 𝑝 = 0.0428) were identified in patients with colorectal cancer. A significant
increase in NETs production in response to fMLP was detected in patients who developed significant postoperative complications
(11,760AFUversus 18,340AFU,𝑝 = 0.0242) andwhohad a prolongedhospital recovery (9,008AFUversus 12,530AFU,𝑝 = 0.0476).
An increase in NETs production was also observed in patients who died, but this did not reach statistical significance. Cancer
location and tumour stage did not appear to affect preoperative NETs production. Conclusions. Patients with colorectal cancer
have significantly increased NETs production in vitro when compared to healthy volunteers, possibly implicating them in cancer
development. Adverse patient outcomes were associated with increased preoperative NETs production, which highlights them as
potential therapeutic targets.
1. Introduction
Neutrophils function as the first line of defence against
infections and are responsible for the containment and
elimination of pathogens. They are prevalent at sites of tissue
trauma and are the hallmark of acute inflammation [1].
Neutrophils are also appreciated to have an important role
in cancer progression and dissemination [2]. It has been
suggested that neutrophils are not a homogenous population
of cells and may consist of protumour and antitumour
subpopulations. The polarisation of neutrophils towards a
protumour or antitumour phenotype may be mediated by
the chemokine landscape in the tumour microenvironment
[3]. Neutrophil Extracellular Traps (NETs) are extracellular
neutrophil derived DNA webs which have been implicated
in cancer progression and in the development of metastases.
NETs have been demonstrated to trap circulating tumour
cells with a subsequent increase in the grossmacrometastatic
disease burden, following tumour cell injection, in a murine
model of infection of caecal ligation and puncture [2].
Activated neutrophils can undergo “NETosis.” This is
an active form of cell death which leads to the release of
decondensed chromatin into the extracellular space [4, 5].
The fibrous structures called NETs constitute a DNA back-
bone containing histones and neutrophil granule products
(myeloperoxidase [MPO]) and cytoplasmic proteins (bacteri-
cidal/permeability-increasing protein [BPI], neutrophil elas-
tase, cathepsin G, and lactoferrin) [6]. The exact mechanism
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for NET formation is not yet completely understood. It is
thought that the ROS pathway is involved as both Nicoti-
namide Adenine Dinucleotide Phosphate Oxidase (NADPH)
and MPO are required for NET formation [5, 7, 8]. The
process of oxidant-dependent NET formation results in
eventual cell death, which is distinct from apoptosis and
necrosis [5, 9].
NETs are recognised as an effective antimicrobial mech-
anism, whereby microbes are trapped and exposed to high
local concentrations of antimicrobials [10]. Conversely, NETs
have been shown to have detrimental effects on the host
with the formation of autoantibodies against chromatin and
neutrophil components [11] and the adherence of platelets
[12], which has implicated them in autoimmune and throm-
boembolic diseases, respectively.
NETs have been implicated in T-cell priming [13] and in
the propagation of antitumour immune responses [14]. Con-
versely, and more frequently, they have been incriminated
in tumour progression and tumour dissemination [15]. The
role of NETs in tumour progression is poorly understood but
the evidence to date proposes an association between intra-
tumoural NET deposition and tumour progression in both
experimental models and in patients with cancer [2, 14, 16].
The ability of tumours to predispose neutrophils to produce
NETs has been demonstrated in murine models and various
tumour types have been shown to predispose circulating
neutrophils to produce NETs via NETosis [17]. The evidence
supports the theory that demonstrates that primary tumours,
through a systemic effect on the host, can induce an increase
in peripheral blood neutrophils that are predisposed to NET
formation.
It is anticipated that a greater understanding of NETs
production in patients with colorectal cancer may help
elucidate their role and prognostic significance. It was there-
fore decided to investigate NET formation in patients with
colorectal cancer and to determine if differences exist in com-
parison to a healthy population. We hypothesised that NET
production may represent a prognostic marker of dysregu-
lated neutrophil function in patients with colorectal cancer.
2. Methods
The study was conducted in accordance with the ethical
principles and was approved by the NRES Committee West
Midlands on 30 December 2013 (13/WM/0485).
2.1. Recruitment of Patients. Patients undergoing an elec-
tive colorectal resection for cancer, within an established
enhanced recovery programme, were identified at the Col-
orectal CancerMultidisciplinary Team (MDT)meeting at the
Heart of England NHS Foundation Trust between 1 January
2014 and 30 June 2015 and patients were followed up until 30
June 2016. All patients over the age of 18whowere undergoing
elective colorectal resection for cancer and were able to give
written informed consent were eligible to be included in the
study. Patients were excluded from the study if they were had
acute presentation, were pregnant, or were breast-feeding or
if consent was refused.
Patient demographics, patient comorbidities, preopera-
tive risk prediction, tumour characteristics, and operative
characteristics were recorded from study participants.
Patient outcomes were collected prospectively and
included the following:
(1) Postoperative complications up to 30 days after
surgery using predefined criteria and graded by the
Clavien-Dindo classification system
(2) Return to theatre within 28 days of the index proce-
dure
(3) Admission to and length of stay on the Intensive Care
Unit
(4) Total hospital length of stay
(5) Readmissions to hospital within 30 days of the index
procedure requiring a hospital stay ≥ 24 hours
(6) 30-Day and 90-day mortality.
Haematological and biochemical parameters were collected
prospectively from the hospital pathology system. These
parameters, in conjunction with physiological indices, were
used to determine a CR-POSSUM, validated, and risk-
adjusted mortality prediction score.
2.2. Recruitment of Healthy Controls. Healthy volunteers
were required to act as controls for patients. They were
recruited from the Birmingham 1,000 Elders Cohort, a
research cohort of healthy volunteers above the age of 60
willing to take part in medical research. To be considered
healthy, participants had to be not suffering from serious
debilitating acute or chronic illness. Well-controlled health
problems, such as hypertension and asthma, did not preclude
enrolment.
2.3. Sample Collection. Patients and healthy controls under-
went peripheral blood tests performed by an experienced
medical practitioner by peripheral venepuncture. Samples
were obtained from patients on the morning of planned
surgery prior to the commencement of any perioperative
interventions.
2.4. Neutrophil Isolation. 4ml of 2% Dextran (Sigma-
Aldrich, Dorset, UK) was added to 24ml of blood and gently
mixed by inversion. The solution was incubated at room
temperature for 30 minutes to sediment the erythrocytes.
The leucocyte-rich plasma was carefully layered on a Percoll
(Sigma-Aldrich) density gradient consisting of 2.5ml of 80%
Percoll and 5ml of 56% Percoll in a 15ml sterile Falcon-
TM tube. This was then centrifuged at 220×g for 20 minutes
at room temperature. The neutrophils were then isolated
from the 80% and 56% gradient interface. The neutrophils
were suspended and subsequently washed in Phosphate-
Buffered Saline (PBS; Gibco, Invitrogen, Paisley, UK). The
resultant supernatant was removed and the neutrophils were
resuspended in RPMI-1640 (Sigma-Aldrich) at a concen-
tration of 1 × 106/ml. The purity and the viability of the
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neutrophil yield were checked using Giemsa stain (Diff-
Quik, Gentaur Europe, Brussels, Belgium) and Trypan-Blue
exclusion, respectively. A purity of ≥95% and a viability of
≥97% were routinely achieved.
2.5. Quantification of Neutrophil Extracellular Trap Forma-
tion. The generation and release of NETs have been shown
to be induced by a variety of internal and pathogen-
derived molecular signals. These signals include chemokines
such as interleukin-8 (IL-8) and lipopolysaccharide (LPS),
formylated peptides such as N-formyl-methionyl-leucyl-
phenylalanine (fMLP), and pharmacological agents, such
as phorbol-12-myristate-13-acetate (PMA). These stimulants
were used in the quantification of Neutrophil Extracellular
Trap assay.
Neutrophils were resuspended in RPMI-1640 with 2 nM
L-glutamine, 100U/ml streptomycin, and 100 ug/ml peni-
cillin (all from Sigma-Aldrich) at a concentration of 1 ×
106/ml. 1 × 105 neutrophils, at a concentration of 1 × 106/ml,
were sited in 20wells of a 96-well flat bottomed plate (Becton-
Dickinson). An additional 75𝜇l of RPMI-1640 with GPS was
added to each well. The neutrophils in 4 wells were then
stimulated with 25𝜇l of each of the following stimulants
(all from Sigma-Aldrich): PMA (1mg/ml [1 : 800 then 1 : 10
dilution]), IL-8 (6.25 𝜇M [1 : 625 dilution]), LPS (1mg/ml
[1 : 1250 dilution]), and fMLP (10mM [1 : 500 dilution]), and
an additional 25 𝜇l of RPMI-1640 with GPS was added as a
negative “unstimulated” control to the 4 remaining wells.The
plate was then incubated for 3 hours at 37∘C with 5% CO2.
Each well was then treated with 200 units of Micrococcal
Nuclease (MNase; Sigma-Aldrich) and 1 𝜇Mof SYTOXGreen
(Gibco, Invitrogen) and incubated for 10 minutes at room
temperature in the dark. This process stained and digested
the extracellular DNA. The contents of each of the wells
were then transferred into individual 500𝜇l Eppendorf tubes
and pelleted at 5000 rpm for 10 minutes. 160 𝜇l of the DNA
containing supernatant was transferred into a black 96-well
flat bottomed plate (Costar, Sigma-Aldrich) and fluorescence
measured in a BioTek-Synergy-2 fluorometric plate reader
(NorthStar Scientific Ltd., Leeds, UK) with a filter setting of
485 nm excitation and 530 nm emission. NETs were recorded
in arbitrary fluorescent units (AFU) and the mean was
calculated from the 4 wells for each stimulant.
A fluorescent microscopy image of the NETs formed
following incubation with 25 𝜇l PMA (1mg/ml [1 : 800 then
1 : 10 dilution]) is shown in Figure 1. The image was created
by immunofluorescencemicroscopy in which cells were fixed
in 2% paraformaldehyde, permeabilized in 0.1% Triton x-
100 (Sigma-Aldrich), and stained with 1 𝜇m SYTOX Green.
Once stained, specimens were mounted in Fluoromount
medium onto glass microscope slides (VWR International)
and visualized using a LEICADMI6000 Bmicroscope (Leica
Microsystems, Milton Keynes, UK) at ×20 objective. Extra-
cellular DNA in the form of a “line” or “cloud” was used to
define the presence of NETs.
2.6. Statistical Analysis. Statistical analysis was performed
using GraphPad Prism Version 6 (La Jolla, California, USA).
Categorical data was analysed using Fisher’s exact tests for
Figure 1: Fluorescent microscopy image of NETs (marked with
arrows) following incubation with 25𝜇l PMA (1mg/ml [1 : 800 then
1 : 10 dilution]).
two variables or 𝜒2 tests for more than two variables. Con-
tinuous data was analysed using nonparametric statistical
models. Mann–Whitney 𝑈 tests were used for independent
samples for two groups. Receiver operator characteristic
(ROC) curves were used to measure how well diagnostic
tests distinguish between two diagnostic groups. All statis-
tical tests performed were two-tailed and the results were
considered significant when 𝑝 < 0.05. Data is represented
graphically using Box-and-Whisker plots which demonstrate
the median, interquartile range, lower extreme (10%), and
upper extreme (90%) of individual data sets.
3. Results
55 patients were identified at the MDT meeting and
approached for inclusion into the study. 45 patients (81.8%)
were successfully recruited into the study and were followed
up for a median of 21.3 months (IQR: 16.7–23.5 months). The
remaining 10 patients refused to give their consent (18.2%).
The median age of the population was 69 years (IQR:
63–75 years) and 26 patients (57.8%) were males. The median
BMI was 26.75 kg/m2 (IQR: 22.5–28.7 kg/m2). 14 patients
(31.1%) had two or more significant comorbidities and 16
patients (35.6%) had an ASA score of 3 or 4. The predicted
mortality of the population, calculated by the CR-POSSUM,
was 2.5% (IQR: 1.3–3.9%).
39 patients (86.7%) were symptomatic and the remain-
ing 6 patients (13.3%) were identified through the NHS
Bowel Cancer Screening Programme. 27 patients (60.0%)
had colonic cancer, whereas 18 patients (40.0%) had rectal
cancer or a cancer of the rectosigmoid junction and 11 patients
(24.4%) underwent neoadjuvant therapy (10, long-course
chemoradiotherapy, and 1, short-course radiotherapy) prior
to surgery. 31 patients (70.5%) had early-stage disease (Dukes’
A or B) versus 13 patients (29.5%) who had late-stage (node
positive or metastatic) disease (Dukes’ C or D).
44 patients (97.8%) underwent surgical resection. 1
patient was deemed unfit for surgery on the day of surgery
and never progressed to surgical resection. 27 procedures
(61.4%) were completed entirely laparoscopically and the
median operative time for all operations was 174 minutes
(IQR: 129–240 minutes). 16 patients (36.4%) underwent
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Table 1: Population characteristics.
Patient demographics 𝑁 = 45
Age, median (IQR) 69.0 (63.0–75.0)
Gender, n (%), M/F 26/19 (57.8/42.2)
BMI, median (IQR), kg/m2 26.8 (22.5–28.7)
Smoking status, n (%), 1/2/3a 9/9/27 (20.0/20.0/40.0)
ASA, n (%), 1/2/3/4 4/25/14/2 (8.9/55.6/31.1/4.4)
Comorbidity, n (%), 0/1/2/≥3 10/21/10/4 (22.2/46.7/22.2/8.9)
Medications, n, 1/2/3/4b 21/9/11/7
CR-POSSUM (predicted mortality [%]), median (IQR) 2.5 (1.3–3.9)
Presentation 𝑁 = 45
Presentation, n (%), 1/2c 39/6 (86.7/13.3)
Cancer location, n (%), 1/2d 27/18 (60.0/40.0)
Tumour characteristics 𝑁 = 44
Neoadjuvant therapy, n (%), y 11 (24.4)
T-Stage, n (%), 0/1/2/3/4 2/2/9/22/9 (4.5/4.5/20.5/50.0/20.5)
N-Stage, n (%), 0/1/2 32/8/4 (72.7/18.2/9.1)
M-Stage, n (%), 0/1 42/2 (95.5/4.5)
Dukes’ stage, n (%), A/B/C/D 9/22/11/2 (20.5/50.0/25.0/4.5)
Differentiation, n (%), 1/2e 39/5 (88.6/11.4)
Extramural venous invasion, n (%), y 14 (32.6)
y: yes; 1/2/3a: active/former/never; 1/2/3/4b: antihypertensive/𝛽-antagonist/antiplatelet/oral hypoglycaemic; 1/2c: symptomatic/screened; 1/2d: colon/rectosig-
moid junction and rectum; 1/2e: well and moderately differentiated/poorly differentiated.
Table 2: Operative characteristics.
Operative characteristics 𝑁 = 44
Operation type, n (%), 1/2a 25/19 (56.8/43.2)
Operation technique, n (%), 1/2b 27/17 (61.4/38.6)
Stoma formation, n (%), y 16 (36.4)
Length of operation (minutes), median (IQR) 174 (129–240)
Postoperative level of care, n (%), 1/2c 27/17 (61.4/38.6)
y: yes; 1/2a: segmental/rectal; 1/2b: laparoscopic/open and laparoscopic
converted to open; 1/2c: ward based care/critical care.
stoma formation, the majority of which were temporary
ileostomies (10 patients [62.5%]) to cover a colorectal anas-
tomosis. 17 patients (38.6%) required admission to Critical
Care Unit following surgery; the majority were planned
admissions (12 patients [70.6%]) and a reflection of the
patients’ comorbidity.
The baseline population characteristics and operative
characteristics are shown in Tables 1 and 2, respectively.
22 patients (50.0%) developed a complication, although
only 6 patients (13.6%) developed a significant complication
(Clavien-Dindo classification ≥ 3).Themedian length of stay
was 8 days (IQR: 5.3–10.1 days) and only 3 patients (6.8%)
were readmitted up to 30 days of the index procedure. 30-Day,
90-day, and 12-month mortality was 2.3%, 4.5%, and 6.8%,
respectively, with a median follow-up of 21.3 months (IQR:
16.7–23.5 months). During the entire study period, 5 patients
(11.4%) died and 4patients (9.1%) developed recurrent disease
but were still alive.
Of the patients that developed complications, the most
frequent were cardiorespiratory events (14) that encompassed
lower respiratory tract infection (4), ischaemic events (4),
arrhythmias (4), and cardiac failure (2). This was followed
by mechanical/functional bowel obstruction (7) and surgical
site infection (7). 3 patients (6.8%) underwent reoperation:
anastomotic repair and defunctioning loop ileostomy (1),
evacuation of haematoma and defunctioning ileostomy (1),
and resuture of abdominal wall (1).
The patient outcomes are shown in Table 3.
Quantification of NET formation was performed in
healthy individuals (𝑛 = 20) and in patients with colorectal
cancer (𝑛 = 45). Populations were well matched with regard
to age (67.5 versus 69.0, 𝑝 = 0.1961) and gender (50.0%males
versus 57.8%males, 𝑝 = 0.5981). Significant increases in NET
production in response to no stimulant (9,735AFU versus
11,347AFU, 𝑝 = 0.0209), IL-8 (8,644AFU versus 11,915 AFU,
𝑝 = 0.0032), and LPS (10,576AFU versus 12,473AFU, 𝑝 =
0.0428) were identified in patients with colorectal cancer.
No significant differences were identified in response to
PMA (42,173AFU versus 39,238AFU, 𝑝 = 0.2353) or fMLP
(9,566AFU versus 12,194AFU, 𝑝 = 0.0868).
NET production in healthy individuals and in patients
with colorectal cancer is displayed in Figure 2.
The impact of cancer location and tumour stage on NET
formation was investigated. No significant differences were
identified in NET production when comparing rectal and
colonic cancers. Similarly, no significant differences were
identified in NET production when comparing early-stage
(Dukes’ A or B) and late-stage (Dukes’ C or D) colorectal
cancers.
The effect of neoadjuvant therapy, which is generally
reserved for high-risk (of local disease recurrence) rectal
cancer with a threatened circumferential resection margin
(<1mm), was also analysed to determine the effect on NET
production. No significant difference in NET production was
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Table 3: Patient outcomes.
Patient outcomes 𝑁 = 44
Complication, n (%), y 22 (50.0)
Clavien-Dindo classification, n (%), I/II/III/IV/V 12/4/2/2/2 (27.3/9.1/4.5/4.5/4.5)
Reoperation, n (%) 3 (6.8)
Critical care admission, n (%), y 19 (43.2)
Total LOS, median (range, IQR) 8.0 (4.0–67.0, 5.3–10.0)
Readmission, n (%), y 3 (6.8)
Disease recurrence, n (%) 4 (9.1)
Mortality, n (%), y
30-Day 1 (2.3)
90-Day 2 (4.5)
12-Month 3 (6.8)
y: yes.
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Figure 2: Box-and-Whisker plot (10th–90th percentile) of NET
production in healthy control subjects (𝑛 = 20) and patients with
colorectal cancer (𝑛 = 45) in response to no stimulant (Unstim),
PMA, IL-8, LPS, and fMLP. Statistical significance, measured by
Mann–Whitney 𝑈 test, is denoted by ∗𝑝 < 0.05 and ∗∗𝑝 < 0.01.
identified when comparing patients who received neoadju-
vant therapy to those who went straight to surgery.
An evaluation of NET formation according to patient
outcome was performed. The patient outcomes investigated
included postoperative complications categorised into minor
complications or no complications (Clavien-Dindo classifica-
tion < 3) and significant complications (Clavien-Dindo clas-
sification ≥ 3), total hospital length of stay (LOS) categorised
into LOS ≤ 5 days and LOS > 5 days, and mortality.
NET production in patients categorised by postoperative
complication, LOS, and mortality is outlined in Figures 3, 4,
and 5, respectively.
An increase in NET production was evident in patients
who went on to develop significant complications (Clavien-
Dindo classification ≥ 3) compared to patients who expe-
rienced minor complications or no complications (Clavien-
Dindo classification < 3). This reached statistical significance
only in response to fMLP (11,760AFU versus 18,340AFU,
𝑝 = 0.0242). Similarly, an increase in NET production was
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Figure 3: Box-and-Whisker plot (10th–90th percentile) of NET
production in patients with Clavien-Dindo classification < 3 (𝑛 =
38) versus Clavien-Dindo classification ≥ 3 (𝑛 = 6) in response
to no stimulant (Unstim), PMA, IL-8, LPS, and fMLP. Statistical
significance,measured byMann–Whitney𝑈 test, is denoted by ∗𝑝 <
0.05.
evident in patients with LOS > 5 days compared to those
with LOS ≤ 5 days. Again, this reached statistical significance
only in response to fMLP (9,008AFU versus 12,530AFU,
𝑝 = 0.0476). Increases in NET production were evident
in patients who died compared to those who survived but
this did not reach statistical significance. It is suggested that
adverse outcomes (Clavien-Dindo classification ≥ 3, LOS
> 5 days, and mortality) are all associated with increased
preoperative NET production (Table 4).
To assess the diagnostic ability of the quantification
of NET formation assay in predicting postoperative com-
plications, a prolonged hospital stay and mortality, ROC
curve analyses were performed in patients with colorectal
cancer who underwent surgical resection. When stimulated
with fMLP, the area under the ROC curve (AUC) values
for the development of a significant complication (Clavien-
Dindo classification ≥ 3), LOS > 5 days, and mortality were
6 International Journal of Inflammation
Unstim PMA IL-8 LPS fMLP
70000
60000
50000
40000
30000
20000
10000
0
N
ET
 p
ro
du
ct
io
n 
(A
FU
)
∗
，／３ ≤ 5 days
，／３ > 5 days
Figure 4: Box-and-Whisker plot (10th–90th percentile) of NET
production in patients who had length of stay≤ 5 days (𝑛 = 9) versus
length of stay> 5 days (𝑛 = 35) in response to no stimulant (Unstim),
PMA, IL-8, LPS, and fMLP. Statistical significance, measured by
Mann–Whitney 𝑈 test, is denoted by ∗𝑝 < 0.05.
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Figure 5: Box-and-Whisker plot (10th–90th percentile) of NET
production in patients who survived (𝑛 = 39) versus those who died
(𝑛 = 5) in response to no stimulant (Unstim), PMA, IL-8, LPS, and
fMLP.
0.7906 (95% CI = 0.6259–0.9553, 𝑝 = 0.0232), 0.6851
(95% CI = 0.5049–0.8652, 𝑝 = 0.0463), and 0.7700 (95%
CI = 0.6018–0.9382, 𝑝 = 0.0512), respectively. The ROC
curve analysis of NET production in response to stimulation
with fMLP for the development of significant postoperative
complications (Clavien-Dindo classification ≥ 3) is displayed
in Figure 6.
4. Discussion
The experiments performed in this study reveal the novel
finding of a significant increase in NET production in vitro in
patients with colorectal cancer compared to a well-matched
cohort of healthy individuals. The experimental findings
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Figure 6: ROC curve of NET production in response to stimulation
with fMLP for Clavien-Dindo classification < 3 (𝑛 = 38) versus
Clavien-Dindo classification ≥ 3 (𝑛 = 6).
support the current evidence that NETs are likely to be
involved in cancer development.
It has been demonstrated, in experimental and animal
studies, that neutrophils play a vital role in the development
ofmetastases, where neutrophils facilitate circulating tumour
cell adhesion to both pulmonary and hepatic endothelial
surfaces [2, 18–21]. It is thought that the direct contact of
circulating tumour cells and neutrophils is an important
precursor to the development of metastatic disease [19,
20]. It is theorised that NETs may act within the primary
tumour and promote tumour progression and dissemination,
although the antimicrobial proteins and peptides associated
with NETs, including Matrix Metalloproteinase-9 (MMP9),
neutrophil elastase, and cathepsin G, have been implicated
in tumour progression without specific reference to NETs
[15]. NETs are thought to expose tumour cells to high
concentrations of biologically active proteins which favour
tumour proliferation and inhibit tumour cell apoptosis. It
is also suggested that NETs support the dissemination of
tumour cells from the primary tumour and promote early
adhesive events and increase sequestration of malignant cells
in end organs [19, 20].
It is also proposed that primary tumours can facilitate
NET production in circulating neutrophils. This effect has
been attributed, in part, to granulocyte colony-stimulating
factor (G-CSF) production by tumours [22]. In addition,
TNF-𝛼 and IL-8 have been shown to facilitate NET formation
and these cytokines are highly expressed by a number of
tumour types, including colorectal cancer [18, 22–24]. The
findings of this study provide additional support to this
theory.
Despite the accumulating evidence that suggests an
association between NETs and tumour progression, the
experimental evidence outlined in this study revealed no
significant differences in NET production in patients with
more advanced disease when patients with early-stage and
late-stage colorectal cancers were compared. In addition, no
significant differences were identified in NET production
in patients treated with neoadjuvant therapy compared to
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Table 4: Stratified results of quantification of NET formation assay.
NET production (AFU),
median (IQR)
Stimulant Healthy control(𝑛 = 20)
Colorectal cancer
(𝑛 = 45) 𝑝 value
Unstimulated 9735 (6429–11840) 11347 (4927–8341) 0.0209
PMA 42173 (35243–52315) 39238 (29497–47988) 0.2353
IL-8 8644 (6098–12304) 11915 (9031–15358) 0.0032
LPS 10576 (7366–12946) 12473 (9381–16542) 0.0428
fMLP 9566 (8345–11973) 12194 (8602–15991) 0.0868
Stimulant Rectal cancer(𝑛 = 18)
Colonic cancer
(𝑛 = 27) 𝑝 value
Unstimulated 10190 (8057–14580) 12140 (9980–1499) 0.2711
PMA 39490 (29050–49190) 38100 (29370–48840) 0.8078
IL-8 11080 (8245–15610) 11960 (9998–15350) 0.4655
LPS 11600 (8515–15580) 12730 (11210–18640) 0.2813
fMLP 10520 (8384–14910) 12440 (9203–16850) 0.4241
Stimulant Early stage (Dukes’ A/B)(𝑛 = 32)
Late stage (Dukes’ C/D)
(𝑛 = 13) 𝑝 value
Unstimulated 11340 (8862–14880) 11350 (7476–15150) 0.7353
PMA 39490 (29640–47200) 38100 (27730–48530) 0.8314
IL-8 11990 (9574–15750) 10320 (7790–14820) 0.3105
LPS 12600 (9783–16280) 11540 (9106–17270) 0.6795
fMLP 12200 (8500–16050) 11780 (8624–14840) 0.6432
Stimulant Neoadjuvant therapy(𝑛 = 11)
Straight to surgery
(𝑛 = 34) 𝑝 value
Unstimulated 9039 (7507–13230) 11780 (9031–15460) 0.1577
PMA 34830 (27140–41590) 40330 (29560–49070) 0.2002
IL-8 10320 (8306–15190) 12010 (9349–15980) 0.2295
LPS 13900 (8323–14930) 12380 (10070–17120) 0.4516
fMLP 11400 (8339–15870) 12330 (8704–17200) 0.4205
Stimulant Clavien-Dindo < 3(𝑛 = 38)
Clavien-Dindo ≥ 3
(𝑛 = 6) 𝑝 value
Unstimulated 11090 (8240–14670) 14780 (12630–18330) 0.0639
PMA 38100 (29620–47760) 40330 (27690–60140) 0.6522
IL-8 11820 (8517–14300) 15840 (11300–19070) 0.0796
LPS 12290 (8858–15750) 15180 (11620–19710) 0.2359
fMLP 11760 (8339–14510) 18340 (12330–22400) 0.0242
Stimulant LOS ≤ 5 days(𝑛 = 15)
LOS > 5 days
(𝑛 = 29) 𝑝 value
Unstimulated 11090 (7507–14200) 12140 (8879–15260) 0.3220
PMA 36430 (27510–43650) 39740 (29500–50280) 0.2760
IL-8 11840 (7935–14200) 12250 (9261–6443) 0.4576
LPS 9408 (6915–15170) 13180 (11250–17270) 0.1812
fMLP 9008 (7599–13290) 12530 (10690–17940) 0.0476
Stimulant Survived(𝑛 = 40)
Died
(𝑛 = 5) 𝑝 value
Unstimulated 11180 (8301–14640) 14760 (10340–18880) 0.2707
PMA 38670 (29640–45400) 50810 (25310–74680) 0.3033
IL-8 11830 (9004–14970) 15370 (10960–20510) 0.1644
LPS 12290 (8982–16280) 13900 (12360–20780) 0.2405
fMLP 11680 (8354–14530) 16110 (12310–23420 0.0533
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patients who went straight to surgery or when comparing
cancer locations.
The systemic inflammatory response can be assessed by
examining changes in concentrations of circulating acute
phase proteins, such as C-reactive protein (CRP), serum
cytokines (tumour necrosis factor-𝛼 [TNF-𝛼], interleukin-6
[IL-6], IL-8, and IL-10), and low levels of circulating albumin
[25, 26]. Preoperatively, these factors have been demonstrated
to be stage-independent prognostic factors in many cancer
types [27–31]. The cellular components of the systemic
inflammatory response, such as neutrophils, lymphocytes,
monocytes, and platelets, have all been reported to have prog-
nostic value in patients with cancer [32–36]. Preoperative
changes in circulating white blood cells and, in particular, the
neutrophil-lymphocyte ratio (NLR) have been used to predict
overall and cancer-specific survival in numerous solid organ
malignancies, including colorectal cancer [37].
Cancer-associated inflammation, both in the systemic
circulation and in the tumour microenvironment, is now
widely recognised to be a key determinant of disease pro-
gression and survival in cancer. A chronic dysregulation of
the immune systemmay account for the persistently elevated
systemic inflammatory response, either as a consequence of
its activation by micro metastases or as a result of disease
which induces tissue injury [38, 39]. It is now established that
the systemic inflammatory response to a tumour is a negative
prognostic factor in primary operable [40] and metastatic
colorectal cancer [41–45]. It is also known that infectious
complications in patients with cancer are associated with
adverse oncological outcomes and an increased mortality as
a consequence of metastatic disease [46–50].
The analysis performed in this study suggests that
adverse patient outcomes (postoperative complications, pro-
longed hospital recovery, and mortality) are associated with
increased preoperative NET production (to all stimulants),
which indicates increased neutrophil activation, conceivably
as a result of cancer-associated inflammation. Significant
increases in NET production in response to stimulation
with fMLP were demonstrated in patients who developed a
postoperative complication (Clavien-Dindo classification ≥
3) and in patients who had prolonged hospital stay (LOS >
5 days). ROC curve analyses were also able to distinguish
between patients who developed postoperative complications
and had a prolonged hospital stay with significance. NETs
production, particularly in response to stimulation with
fMLP, therefore has potential prognostic significance and
further investigation into their predictive value is justified.
fMLP stimulation of neutrophils activates a wide variety of
intracellular signaling pathways mediated by phospholipase
C (PLC), phospholipase D (PLD), phospholipase A2 (PLA2),
phosphatidylinositol 3-kinase (PI3K), and mitogen-activated
protein kinases (MAPKs) to induce various cellular functions
[51]. Both PLC and PLD have been reported to be involved in
superoxide generation and degranulation of neutrophils [52,
53] and this may explain the experimental findings observed
in this analysis.
A dysregulated neutrophil function in patients with
colorectal cancer may conceivably be attenuated by periop-
erative immune-modulatory therapies. These therapies aim
to suppress nonspecific systemic inflammation and maintain
an effective antitumour, cell-mediated immunity of the host
which may assist the clearance of circulating tumour cells
and the development of occultmetastases [54]. Accumulating
evidence suggests that simple immune-modulatory strategies
(anti-inflammatory agents [nonsteroidal anti-inflammatory
drugs] or immune-modulatory therapies [corticosteroids
and HMG-CoA reductase inhibitors (statins)]) could be
safely implemented in the perioperative period [55]. There
is increasing evidence that immune-modulatory therapies
are able to modulate neutrophil function. In particular,
statins have been demonstrated to reduce the neutrophil
infiltrate following LPS challenge in bronchoalveolar lavage
fluid taken from patients with sepsis [56]. Statins have also
been shown to increase NET formation in healthy individ-
uals with the consequent elimination of bacteria in vitro
[57]. Furthermore, during bacterial pneumonia-associated
sepsis, NET production is suppressed with improvements
occurring during sepsis resolution [58]. It has been proposed
that neutrophil functional defects may be restored by the
administration of statins [58]. NETs could therefore represent
potential therapeutic targets and modulation of neutrophil
dysregulation, as a consequence of cancer-associated sys-
temic inflammation, may be possible.
This experimental study has a number of limitations.
Firstly, the population evaluated was small and heteroge-
neous with regard to patient demographics, patient comor-
bidities, tumour characteristics, and operative characteristics,
making interpretation of the results difficult and limiting
the generalisability of the study’s findings. Secondly, com-
parative analyses stratifying patients according to cancer
location, cancer stage, and patient outcomes are subject to
misinterpretation as potential confounding variables were
not accounted for. Thirdly, the number of adverse patient
outcomes in the study population was low, making inter-
pretation of patient outcomes challenging. Fourthly, in vitro
experiments performed to assess neutrophil function were
conducted outside of the biological context and consequently
there are challenges in extrapolating the results and it must
be acknowledged that they cannot be readily transposed
to and predict the reaction of the entire organism in vivo.
Lastly, in healthy controls and in patients with colorectal can-
cer, significant increases in NET production were apparent
when comparing unstimulated neutrophils with neutrophils
stimulated with PMA and LPS. No significant differences
were evident when comparing unstimulated neutrophils with
neutrophils stimulated with IL-8 or fMLP.Thismay represent
inadvertent neutrophil activation when processing unstimu-
lated neutrophils or failure of induction of NET formation in
response to stimulation with IL-8 and fMLP.
5. Conclusion
NETs have been incriminated in tumour progression and dis-
semination and it is suggested that tumours may predispose
circulating neutrophils to produce NETs. The experimental
findings revealed significantly increased NET production in
patients with colorectal cancer when compared to a healthy
control population and this contributes to the evidence that
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NETs are possibly implicated in cancer development. It has
also been demonstrated that adverse patient outcomes, that
is, postoperative complications, prolonged hospital stay, and
mortality, were all associated with increased preoperative
NETproduction. It is therefore conceivable thatNETproduc-
tion may play a pathophysiological role for the development
of adverse outcomes. NETs represent potential therapeutic
targets and merit further investigation in the context of
colorectal cancer.
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